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Abstract
Gastrointestinal (GI) defects, including gastroesophageal reflux, constipation and delayed
gastric emptying, are common in patients with spinal muscular atrophy (SMA). Similar GI
dysmotility has been identified in mouse models with survival of motor neuron (SMN) protein
deficiency. We previously described vascular defects in skeletal muscle and spinal cord of
SMA mice and we hypothesized that similar defects could be involved in the GI pathology
observed in these mice. We therefore investigated the gross anatomical structure, enteric
vasculature and neurons in the small intestine in a severe mouse model of SMA. We also
assessed the therapeutic response of GI histopathology to systemic administration of mor-
pholino antisense oligonucleotide (AON) designed to increase SMN protein expression.
Significant anatomical and histopathological abnormalities, with striking reduction of vascu-
lar density, overabundance of enteric neurons and increased macrophage infiltration, were
detected in the small intestine in SMAmice. After systemic AON treatment in neonatal
mice, all the abnormalities observed were significantly restored to near-normal levels. We
conclude that the observed GI histopathological phenotypes and functional defects
observed in these SMA mice are strongly linked to SMN deficiency which can be rescued
by systemic administration of AON. This study on the histopathological changes in the gas-
trointestinal system in severe SMA mice provides further indication of the complex role that
SMN plays in multiple tissues and suggests that at least in SMA mice restoration of SMN
production in peripheral tissues is essential for optimal outcome.
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Introduction
Spinal muscular atrophy (SMA) is one of the most common genetic diseases in childhood and
the leading genetic cause of infant mortality [1]. It is characterized by progressive degeneration
of spinal motor neurons leading to proximal skeletal muscle atrophy and paralysis. SMA is
caused by functional loss of the survival of motor neuron (SMN) protein resulting from homo-
zygous genomic deletion or mutations of the survival of motor neuron 1 (SMN1) gene. There
are two SMN genes in humans, the telomeric SMN1 and its centromeric homolog SMN2, a
result of intrachromosomal duplication of 5q13. SMN1 differs from SMN2 by several exonic
and intronic single nucleotide polymorphisms, without any amino acid substitution. However,
a single nucleotide (C to T) variation at position 6 in exon 7 affects the efficiency of splicing of
this exon in the SMN2 gene, leading to approximately 90% of transcripts lacking exon 7 [2,3].
The resulting truncated protein is nonfunctional and unstable. The remaining 10% fully tran-
scribed product is not sufficient to compensate for the loss of the SMN1 gene. The copy num-
bers of SMN2 gene, which vary in the general population, are important in modulation of
disease severity [4–6].
SMA is currently incurable, however significant progress in the development of experimen-
tal therapies has been achieved in recent years. Promising results from preclinical studies in
animal models on antisense oligonucleotide (AON) therapy [7–10], small molecular therapy
[11,12] and adenoviral vector mediated SMN1 gene therapy [13–16] have facilitated the appli-
cation of these therapeutic approaches in clinical trials. Intrathecal administration of Nusiner-
sen (IONIS-SMNRx), an 18-mer AON in 2’-O-2-methoxyethyl (MOE) phosphorothioate
chemistry that targets the intronic splicing silencer N1 element (ISS-N1) in intron 7 of SMN2
gene, in severe SMA infant is now in phase III clinical trials with encouraging data in safety
and clinical outcome measurement from the previous phase I clinical trial [17]. Small mole-
cules and SMN1 gene therapy are both in the early phases of clinical trials (www.clinicaltrials.
org. ID: NCT02268552; NCT02240355 and NCT02122952).
SMN protein is ubiquitously expressed. While SMA has traditionally been classified as a
selective lower motor neuron disease with spinal motor neurons in the anterior horn being the
primary pathological target, an increasing number of clinical and experimental reports suggest
that pathologies in peripheral systems could contribute to the disease progression, especially in
cases at the severe end of the clinical spectrum [18, 19]. It is therefore important to characterize
the involvement of different peripheral organs in SMA.
Children with SMA can suffer from a variety of functional gastrointestinal (GI) complica-
tions, such as gastroesophageal reflux, constipation, abdominal distension and retarded gastric
emptying [20]. Similar GI functional defects have been reported in mice with Smn deficiency,
including constipation, delayed gastric emptying, slow intestinal transit and reduced colonic
motility [21]. Vascular defects have also been reported in severe cases of SMA [22,23] and in a
variety of transgenic mouse models of SMN deficiency [24–26]. Digital necrosis and distal vas-
cular thrombosis have also been reported in severe SMA infants [22,23]. Our group and others
recently reported decreased vascular density in skeletal muscle biopsies and spinal cord tissues
in the severe SMA transgenic mice [26,27]. We have also demonstrated defective microvascular
development in skeletal muscle biopsies in young SMA patients [27]. We therefore hypothe-
sized that the previously reported GI functional abnormalities in SMA mice could be related to
a vascular abnormality in the SMAmice.
In this study, we show significant alterations in gross and microscopic anatomy of the GI
tract in SMAmice, including a decrease in vascular density, and an increase in the number of
enteric neurons and macrophages in small intestine. In addition, we show rescue of these histo-
pathological defects in SMAmice in response to systemic AON treatment via administration
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of the therapeutic morpholino antisense oligomer PMO25. Our findings provide compelling
evidence of the involvement of gastrointestinal tract in SMA, at least in this mouse model,
which might well have implications for future therapeutic development.
Materials and Methods
Animals
The Taiwanese SMA transgenic mice FVB.Cg-Tg(SMN2)2Hung SMN1tm1/Hung /J, originally
created by Hsieh-Li et al. [28], were purchased from Jackson Laboratory (TJL005058; Jackson
Laboratory, Bar Harbor, ME). Mice were bred and experimental procedures were performed
according to protocols approved by University College London (London, UK) Biological Ser-
vices and UK Home Office under the Animals (Scientific Procedures) Act 1986. The severe
SMAmice, with genotype of (SMN2)2
+/-; Smn-/-, have two copies of human SMN2 transgene
and homozygous knockout of endogenous mouse Smn, are referred to SMAmice in this study.
The heterozygous non-phenotypic control mice, with genotype of (SMN2)2
+/-; Smn+/-, are
referred to controlmice in this study.
AON treatment in SMAmice
The AON used in this study is a 25-mer morpholino antisense oligomer, PMO25, which is
designed to augment the splicing of exon7 in SMN2 gene by targeting the ISS-N1 element in
intron 7. This therapeutic target was originally identified by Singh et al [29], and has been
approved to be the most efficient AON target so far in augmenting exon 7 splicing in SMN2
gene [7–10]. We have previously reported the successful rescue of the severe SMA mouse
model after PMO25 treatment [10,30]. PMO25 was synthesized by Gene Tools (Philomath,
OR) for research use only. SMA mice were injected with a single dose of 40 μg/g morpholino
antisense oligomer PMO25 subcutaneously at postnatal day 0 (PND 0). The PMO25 treated
severe SMAmice are referred to SMA+PMO25 in this study. Subcutaneous administrations
were injected into the upper part of the back using a 10μl glass capillary (Drummond Scientific
Company, Pennsylvania).
Intestine tissue processing
Mice were weighed before being culled by a schedule 1 procedure at PND10 where PND0 is
designated as the day of birth. The entire intestine was collected and its length was measured.
The whole bowel length was defined as the length from proximal duodenum to anal region.
Small bowel was measured from proximal duodenum to ileocecal junction. The proximal duo-
denum (1 cm from pyloric region) and distal ileum (1 cm from ileocecal junction) were dis-
sected and embedded in optimal cutting temperature (OCT, CellPath, UK) in a mould and
frozen in liquid nitrogen-cooled iso-pentane. Adjacent duodenum segments were snap frozen
in dry ice and stored at -80°C for RNA extraction and western blotting procedures.
Histopathology
At least five 3 μm transverse and longitudinal cryosections from the duodenum and ileum of
each mouse, taken at 60 μm intervals, were prepared using a cryostat (Leica, Germany) and
were stained with haematoxylin and eosin (H&E). Slides were viewed under a light microscope
(Axioplan 2, Germany) (5× objective, 0.15NA and 20× objective, 0.5NA). Images were cap-
tured using AxioCamHRc (Rev3) and a minimum of 10 fields per section were evaluated.
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Immunohistochemistry
Sections were cut at 10 μm and randomly oriented on the slide. Five cryosections at 50 μm
intervals from each mouse intestine were used for staining. Cryosections were dried for 20 min-
utes then fixed in 4% paraformaldehyde (PFA) for 20 minutes and rinsed in phosphate-buff-
ered saline (PBS) for 2 minutes at room temperature. All sections were subjected to
immunohistochemical analysis using primary and secondary antibodies listed in Table 1.
For PGP9.5 primary antibody staining, sections were subjected to antigen retrieval by boil-
ing slides in 20mM citrate buffer (Thermo Scientific) for 15 minutes, and blocked in PBS/M.O.
M (mouse IgG blocking reagent, Vector) for 1 hour at room temperature. After incubation
with primary antibodies at room temperature for 1 hour, slides were rinsed in PBS/0.03% Tri-
ton for 2 minutes twice followed by incubation in secondary antibody for 1 hour. Slides were
then rinsed twice with PBS/0.03% Triton for 2 minutes and mounted with hydromount
(National Diagnostics) and DAPI (1:1500, Hoechst 33342, ThermoFisher Scientific) for
nuclear staining.
Imaging and quantification
Images were captured on a fluorescence microscope (Leica DM4000B, Germany) (HCX PL
fluotar 2x/0.50 PH2) using Metamorph software (Molecular Device, Palo Alto, CA). A mini-
mum of 10 equidistant images per transverse section were collected from the entire gut tube
wall, which were used for all subsequent analysis. All images were analyzed and quantified
using imageJ software (http://imagej.nih.gov/ij/). For vascular density, a region of interest of
intestinal tissue was identified by DAPI staining and the number of vWF positive pixels was
quantified and expressed as blood vessel density (pixels per unit area). In a similar manner the
calculation of PGP9.5 positive pixels per unit area was used to indicate the density of ganglia of
the enteric nervous system seen as myenteric or Auerbach’s plexuses, which lie along the neu-
romuscular ridge of the intestinal wall. The total numbers of PGP9.5 positive neurons along
the gut tube walls in the transverse sections were counted and a mean was calculated. The total
numbers of F4-80 positive macrophages present in each section were counted and mean was
calculated per mouse.
RT-PCR and western blotting
Duodenum samples were homogenized using a Precellys Homogenizer (Berlin Technologies)
in RLT lysis buffer using RNeasy Mini Kit (Qiagen, Chatsworth, CA). Total RNA extraction
and reverse-transcription were performed as described previously [10,31]. The ratio of full-
Table 1. Antibodies used in immunohistochemical analysis.
Antibodies Host Dilution Catalogue number and source
Primary antibodies
von Willebrand factor (vWF) Rabbit 1:500 AB7356, Merck Millipore
Protein Gene Product 9.5 (PGP9.5) Rabbit 1:100 Rb-9202, Neomarkers
Smooth Muscle Actin Mouse 1:100 M0851, Dako
F4-80 Rat 1:50 MCA497GA, AbD Serotec
Secondary antibodies
Alexa Fluoro1594 Anti-rabbit IgG (H+L) Goat 1:500 A11037, Invitrogen
Alexa Fluoro1488 Anti-mouse IgG (δ2a) Goat 1:500 A21131, Invitrogen
Alexa Fluoro1594 Anti-rat IgG (H+L) Goat 1:500 A11007, Invitrogen
doi:10.1371/journal.pone.0155032.t001
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length SMN2 to Δ7 SMN2 transcripts was quantified by quantitative real-time RT-PCR. The
expression of human SMN protein was measured by western blotting as previously described
[31]. β-tubulin was used as loading control in all samples. Blots were developed with an
enhanced chemiluminescence detection kit (Bio-Rad, California, USA). Semi-quantification of
band intensity was analyzed by imageJ software.
Statistical analysis
Data are presented as mean ± standard error of the mean (mean ± SEM). One-way ANOVA
and post t-test were used to determine statistical significance when comparing 2 and 3 groups
of mice. GraphPad Prism 5.0 software was used for statistical analysis and graph design.
Results
Decreased body weight and bowel length in SMAmice
The severe SMAmice have extremely shortened lifespan and distinctly small body size. These
phenotypes can be successfully rescued by systemic morpholino antisense oligomer treatment
[10, 30]. To determine the general condition of the GI system in the severe SMAmice and the
response to systemic PMO25 treatment, we measured the length of intestine and the body
weight (Fig 1A and 1B). There was a significant reduction in the length (mm) of the intestine
in SMAmice (total length: 99.71 ± 5.63 N = 7; small intestine: 91.25 ± 3.14 N = 4) compared to
control mice (total length: 208.7 ± 9.28 N = 6; small intestine: 186.3 ± 4.33 N = 3; P<0.0001)
(Fig 1A, 1C and 1D). There was also a significant reduction in body weight (gram) in SMA
mice (1.75 ± 0.08 N = 4) compared to control mice (5.52 ± 0.07 N = 3; P<0.0001) (Fig 1E).
However, the relative length of intestine to body weight (mm/g) in SMAmice (relative total
intestinal length: 63.37 ± 1.17 N = 4; relative small intestinal length: 52.19 ± 0.81 N = 4) was
significantly higher than those in control mice (relative total intestinal length: 40.86 ± 1.22
N = 3, P<0.0001; relative small intestinal length: 33.74 ± 1.05 N = 3, P<0.0001) (Fig 1F and
1G). This suggests that SMAmice, though very small, had disproportionately long intestines
compared to control. After PMO25 treatment, both the body weight (4.06 ± 0.25 N = 4;
P<0.001 vs SMA) and bowel length (total length: 191.0 ± 4.03 N = 7; small intestine:
161.0 ± 5.75 N = 4; P<0.001 vs SMA) were significantly restored to near-normal levels (Fig 1C,
1D and 1E). PMO25 treated mice also showed a significant reduction in the relative length of
the full (48.07 ± 2.04 N = 4; P = 0.0006 vs SMA) and small intestine (39.91 ± 1.63 N = 4;
P = 0.0005 vs SMA) (Fig 1F and 1G). This indicates that AON treatment has restored body
weight and relative length of the intestines to near-normal values.
Histopathological defects in the small intestine of SMAmice
We next carried out a histological evaluation of the microstructure of duodenum in H&E
stained transverse sections. Distinct histopathological abnormalities were present in SMAmice
compared to controls (Fig 2A and 2B), and were dramatically improved after systemic PMO25
treatment (Fig 2C). Villi, the characteristic finger-like projections of the wall of the small intes-
tine, in SMAmice were blunted (Fig 2B) and significantly reduced in length (139.6 ± 13.95 μm,
N = 3) compared to control mice (215.7 ± 7.59 μm, N = 3; P<0.01) (Fig 2D). Diffused edema
of the lamina propria, which underlies the epithelial layer of the gut tube, was also noted in
SMA intestine (Fig 2B). These observations are consistent with previous findings in the Tai-
wanese SMAmouse model [32]. In addition the intestinal crypts (which lie between and at the
base of projecting villi) were irregular in size, shape and distribution in SMAmice (Fig 2B).
The depth of crypt in SMAmice (42.19 ± 7.60 μm, N = 3) was significantly greater than in
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control mice (24.36 ± 2.43 μm, N = 3; P<0.05) (Fig 2E). After systemic PMO25 treatment, all
the histopathological alterations described above were significantly improved, with the length
of villi (203.6 ± 16.48 μm, N = 3; P<0.05 vs SMA; no significance vs control; Fig 2D) and depth
of crypts (30.55 ± 3.00 μm, N = 3; no significance vs control; Fig 2E) significantly improved to
near-normal levels.
Significantly decreased vascular density in SMAmouse small intestine
We and others recently reported decreased vascular density in skeletal muscle and spinal cord
in SMAmice [26,27] and in muscle from young SMA patients [27]. To assess the relationship
between the involvement of vascular developmental abnormalities in the gut and its relation-
ship to the observed gut phenotype in SMA, we measured the vascular density in the small
intestine in SMA mice. VonWillebrand factor (vWF) immunofluorescence staining in duode-
num and ileum (Fig 3A) revealed a dramatic decrease in vascular density in SMAmice. There
was a significant reduction of blood vessel density in both duodenum (75% reduction) and
ileum (65% reduction) in SMA mice compared to littermate controls (Fig 3B and 3C). The
Fig 1. Gross anatomical features of the bowel in SMA, control and PMO25 treated SMAmice. (A)
Images of the whole bowel from 10 day old SMA (N = 3), control (N = 3) and PMO25 treated SMAmice
(N = 3). Specimens were pinned in order to display the whole bowel length. Arrows indicate proximal
duodenum and arrowheads identify the cecum. (B) Representative image of SMA and PMO25 treated SMA
mice at PND10. (C) SMAmice had the shortest whole bowel length compared to control and PMO25 treated
mice. (P< 0.0001 vs control and vs SMA+PMO25. N = 6–7). (D) The mean small bowel length was
significantly lower in SMAmice than in control and treated mice (P< 0.0001 vs control and vs SMA+PMO25 in
small bowel. N = 3–4). (E) SMAmice displayed the lowest body weight compared to control and PMO25
treated mice. (P< 0.0001 vs control and P<0.0001 vs SMA+PMO25. N = 3–4). The relative total intestine
length to body weight (F) and relative small intestinal length to body weight (G) in SMAmice were significantly
higher than those in control and PMO25 treated mice (P<0.0001 N = 3–4). ***P < 0.001, *P<0.05.
doi:10.1371/journal.pone.0155032.g001
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decreased vascular density in both duodenum and ileum was significantly improved in SMA
mice after systemic PMO25 treatment (P<0.01 and P<0.05 vs SMA in duodenum and ileum,
respectively), to near-normal levels (no significance between SMA+PMO25 and control; Fig
3B and 3C).
Significant increase in enteric neuron numbers in SMAmouse small
intestine
The autonomic nervous system acting through the enteric nervous system (ENS) is responsi-
ble for the regulation and control of all gastrointestinal functions. Disrupted ENS signaling
in intestine, resulting in defective GI function, has been reported in the adult stage of two
mild mouse models of Smn deficiency [33]. In this study, we examined enteric neurons in the
severe Taiwanese SMA mouse model, which has a severe phenotype and short lifespan. Gan-
glion density and neuron numbers in the myenteric plexuses were identified and quantified
by PGP9.5 staining. To identify the muscular layer of the intestine wall, α-smooth muscle
actin staining was used to discriminate myenteric from submucosal plexuses. Unexpectedly,
the area occupied by ganglia of the myenteric plexus was significantly increased in SMA mice
with more closely-packed neurons compared to control mice (Fig 4). The number of neurons
and ganglion density in the myenteric plexuses were significantly greater in SMA compared
to control mice, in both duodenum (ganglion density: 256.7±51.6 vs 132.7±10.7, N = 4,
P<0.05; neurons: 156.9±16.3 vs 93.8±8.3, N = 6–8, P<0.01) and ileum (ganglion density:
137.9±22.6 vs 63.8±16.0, N = 4, P<0.05; neurons: 89.4±10.9 vs 65.1±3.6, N = 6–8, P<0.05).
The ganglion density and number of neurons were significantly reduced to near-normal
Fig 2. Histology of small intestine.H&E staining of (A) Control (B) SMA (C) SMA+PMO25 small intestine. Shortened and blunted villi (* asterisk)
and intramural edema (^ arrow head) were present in the lamina propria layer in SMAmice, along with the distinct intestinal crypt architectural
distortion (arrow). Quantification of the villus length (D) and crypt size (E) in mice. **P < 0.001, *P < 0.05. Scale bar = 100 μm.
doi:10.1371/journal.pone.0155032.g002
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levels after PMO25 treatment in both duodenum (ganglion density: 256.7±51.6 (SMA) vs
136.5±21.9 (SMA+PMO25), N = 4, P<0.05; neuron number: 156.9± 16.3 vs 65.4± 8.1, N = 8,
P<0.001) and ileum (ganglion density: 137.9±22.6 and 71.8±11.0, N = 4, P<0.05; neuron
number: 89.4±10.9 vs 59.0±5.4, N = 8, P<0.05). There was no significant difference between
all parameters in control and SMA+PMO25 mice (Fig 4).
Increased macrophage infiltration in intestine of SMAmice
An excess of enteric neurons has been reported in patients with inflammatory bowel disease
[34,35]. The correlation between enteric neuron density and the severity of intestinal inflam-
mation has also been indicated in transgenic mice with aberrant numbers of neurons in the
ENS [21]. To understand if the increased number of enteric neurons in the intestine of severe
SMAmice is correlated with inflammation, macrophage infiltration was examined in duode-
num and ileum segments from SMA, control and PMO25 treated SMAmice. Significantly
increased macrophage numbers were observed in the intestine of SMAmice (23.20 ± 1.74,
N = 6 in duodenum; 21.05 ± 1.69, N = 6 in ileum) compared to control mice (16.40 ± 2.91,
N = 6 in duodenum, P<0.05; 8.10 ± 1.65, N = 6 in ileum, P<0.01; Fig 5). The numbers were
significantly reduced to near-normal levels after PMO25 treatment (13.17 ± 1.93, N = 6 in
Fig 3. Blood vessel density in duodenum and ileum. (A) Representative image of vWF Immunofluorescence staining in duodenum and ileum of
small intestine in control, SMA and PMO25 treated SMAmice. Blood vessels were indicated by vWF (red) staining. DAPI (blue) stains DNA nuclear
and was used to outline the intestinal structure. Proportion of vascular density in duodenum (B) and ileum (C). The vascular density was quantified as
pixels/unit area using imageJ software. Values in all three groups were then normalized to the mean value in the group of untreated SMAmice.
Vascular density was significantly reduced in SMAmice in duodenum (P < 0.001 vs control, P <0.01 vs SMA+PMO25) and ileum (P < 0.05 vs control,
P<0.05 vs SMA+PMO25), and was significantly improved after PMO25 treatment. (* P < 0.05, ** P<0.01). Scale bar = 50 μm.
doi:10.1371/journal.pone.0155032.g003
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duodenum, P<0.01 vs SMA; 14.92 ± 2.90, N = 5 in ileum, P<0.05 vs SMA). There was no sig-
nificant difference in macrophage numbers between control and SMA+PMO25 mice.
Systemic administration of PMO25 augments exon 7 inclusion and
restores SMN protein in intestine of SMAmice
We have previously shown that systemic administration of PMO25 successfully rescues severe
SMAmice [10]. A significant increase in SMN2 exon 7 inclusion and SMN protein were
detected in the central nervous system after PMO25 was delivered subcutaneously in severe
SMAmice on PND0, in keeping with the incomplete blood brain barrier function in newborn
mice [10]. In addition, we have also demonstrated that regular systemic administration of low-
dose PMO25 at later stage can still benefit SMA mice with intermediate phenotypes, and sug-
gest that restoration of SMN in peripheral systems, in addition to CNS restoration, is important
for SMA treatment [30]. To determine the efficiency of AON therapy on SMN expression in
intestine, SMN2 exon 7 inclusion and the expression of SMN protein in duodenal segments
were assessed by quantitative real-time PCR and western blotting, respectively. The ratio of
full-length SMN2 to Δ7 SMN2 transcripts in intestine was significantly increased after systemic
PMO25 treatment (P = 0.014; Fig 6A and 6B). SMN protein was increased approximately
2-fold in intestine after PMO25 treatment (Fig 6C and 6D).
Fig 4. Enteric neurons in SMAmouse small intestine. (A) Representative image of enteric neurons/ganglions in Duodenummyenteric plexuses from
control, SMA and PMO25 treated SMAmice. Enteric neurons were stained with neuronal marker PGP9.5 (red). The muscular layer was stained with α-
smooth muscle actin (green). Cell nuclei were stained with DAPI (blue). (B) Relative ganglion density in 3 groups of mice. Pixels of PGP9.5 immunostaining
per captured field was used to quantify the ganglion density using imageJ software and expressed as pixels per unit area. Ganglion density was significantly
increased in SMAmice in both duodenum (P = 0.028 vs control, N = 4 per group) and ileum (P = 0.018 vs control, N = 4 per group) and significantly
decreased after PMO25 treatment (P = 0.038 in duodenum; P = 0.019 in ileum; N = 4 per group). (C) The mean number of neurons was also significantly
increased in both duodenum (P = 0.0045 vs control, P< 0.001 vs PMO25 treatment) and ileum (P = 0.04 vs control, P = 0.012 vs PMO25 treated SMA) in SMA
mice and was reduced significantly by PMO25 treatment (N = 6–8, * P < 0.05; ** P < 0.01; *** P < 0.001). Scale bar = 25 μm.
doi:10.1371/journal.pone.0155032.g004
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Discussion
Here we describe detailed morphological changes in a severe mouse model of SMA, including
gross and microscopic structural changes in addition to an unexpected increase in the extent of
the enteric nervous system and in inflammation identified by macrophage infiltration of the
small intestine. In each case, these significant structural, and likely functional, defects in the
small intestine are restored to near-normal values by systemic treatment with an AON
designed to increase SMN2 exon 7 inclusion.
The striking morphological changes in the small intestine of SMAmice—shortened and
blunt villi, intramural edema in the lamina propria layer of the intestinal wall and enlarged
intestinal crypts (Figs 1 and 2)—are consistent with a previous report of pathological features
in the intestine of severe SMAmice [36]. We were surprised to find that the relative length of
Fig 5. Increasedmacrophage infiltration in the gut of SMAmouse. (A) Representative image of macrophage staining in duodenum segment in
SMA, control and PMO25 treated mice. Macrophages were stained with F4-80 antibody (green) and nuclei were stained with DAPI (blue). The
absolute macrophage numbers per area in duodenum (B) and ileum (C) in three groups of mice. (N = 6. * P < 0.05; ** P < 0.01). Scale bar = 25 μm.
doi:10.1371/journal.pone.0155032.g005
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intestine to body weight in SMAmice was longer than expected. This may be due to the steep
body weight loss during the end stage of the rapidly progressive disease in mice.
Due to limitations related to the severe phenotype and short lifespan, we did not perform
the GI functional assays in the severe SMAmice. However, studies in less severe adult SMA
mice have already clearly demonstrated the direct impact of Smn deficiency on GI function
[33]. Despite normal activity levels and food and water intake, transgenic mice with nestin-cre-
mediated recombination of mouse Smn on the SMNΔ7 background had constipation, delayed
gastric emptying, slow intestinal transit and reduced colonic motility [33]. Malnutrition and GI
dysmotility are also a common manifestation in SMA type I and II patients [20,37]. The intesti-
nal problems in SMA patients have been proposed to result from GI tract smooth muscle weak-
ness secondary to the inadequacy of the autonomic ENS [18]. However, evidence from our
study suggests another possibility: that impaired GI function may be associated with a reduc-
tion in vascular density and an increase in inflammation in the intestine.
Decreased vascular density has been reported in skeletal muscle and spinal cord in severe
mouse models of SMA [26,27]. In patients, vascular defects such as digital necrosis and distal
vascular thrombosis have been reported in severe SMA infants [22,23]. There is reduced vascu-
lar density in skeletal muscle in severe SMA patients and the vascular system in muscle fails to
develop with age [27]. In this study, we show a striking reduction in vascular density in the
small intestine of severe SMAmice (Fig 3). These mice presented significant weight loss,
Fig 6. Systemic delivery of PMO25 increased SMN2 exon 7 inclusion and SMN protein expression in intestine. (A)
Representative image of reverse transcriptional polymerase chain reaction (PCR) showed the partial increase of full-length SMN2
in SMAmice after PMO25 treatment. (B) Quantitative real-time PCR of full-length SMN2 to Δ7 SMN2 transcript ratio. (C) Western
blotting assay of human SMN protein in intestine tissues from SMA and PMO25 treated SMAmice. β–tubulin was used as loading
control. (D) Semi-quantification of SMN protein relative to tubulin control. Data were normalized to the ratio of SMN/tubulin in
untreated SMAmice. (N = 3, *P< 0.05)
doi:10.1371/journal.pone.0155032.g006
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malnutrition, reduced mobility and diarrhea at the end stage of their lives, resembling the clini-
cal presentation of patients with rare chronic mesenteric ischemia [38]. This appearance could
therefore be linked to tissue hypoxia due to vascular defects, which was suggested in our previ-
ous studies in spinal cord in severe SMAmice [27]. Close interactions between the enteric ner-
vous and vascular systems are indicated in vitro in cell culture assay of vascular cells and ENS-
derived cells, in vivo in tyrosine kinase receptor RET knockout enteric ganglia deficiency mice
and in human Hirschsprung’s disease [39]. Interestingly, contradictory data exists from mouse
models and patients with enteric ganglia deficiency: with a reduction of blood vessel density in
the RET knockout mouse model, but more blood vessels detected in the enteric aganglionic
zone of patients with Hirschsprung’s disease [39]. We report similar inconsistencies in vascular
density and enteric neuron numbers between SMAmice and patients. While the numbers of
enteric neurons and ganglion density in duodenum and ileum were dramatically increased in
SMAmice (Fig 4), a study conducted in 8 infants with Werdnig-Hoffmann disease (SMA type
I) shows low values of neural tissue in myenteric plexus in small intestine and colon [40].
The increased numbers of enteric neurons found in severe SMAmice could be either a com-
pensatory mechanism to help maintain GI function, or a response to other underlying patho-
genic changes. Overabundance of enteric neurons has been reported in inflammatory bowel
disease [34,35], where macrophage infiltration is implicated in disease pathogenesis [41]. We
found a significant increase in numbers of macrophages in small intestines of SMAmice (Fig
5). The severity of intestinal inflammation has been shown to be associated with the density of
the enteric neurons in transgenic mice with either hyperplastic or hypoplastic ENS [21]. We
show a similar correlation between enteric neuron overabundance and increased inflammation
in intestine in SMAmice. It is therefore tempting to speculate that the overabundance of
enteric neurons and ganglia may be a response to the increased macrophage infiltration in the
intestine in SMA mice.
Importantly, we show that histopathological abnormalities in intestine in severe SMAmice
are significantly improved by systemic PMO25 treatment. The morpholino antisense oligomer
PMO25 has been previously reported by our group to effectively augment SMN2 exon 7 inclu-
sion and restore SMN protein in SMN deficiency mouse models [10,30]. Systemic administra-
tion of a single 40 μg/g dosage on PND0 completely rescues severe SMAmice by increasing the
lifespan from 10 days to over 200 days. Significant restoration of SMN was detected in brain
and spinal cord after the systemic delivery of PMO25 in newborn SMAmice when the blood
brain barrier is still penetrable [10]. In addition, chronic systemic administration of PMO25 at
a later adult stage in SMA mice with intermediate phenotypes also showed the beneficial effect
on disease progression [30]. The latter study also indicates the involvement of peripheral
organs in disease pathogenesis. In this study we extend the involvement of the GI system in
SMA and demonstrate its responsiveness to systemic AON treatment.
By analyzing SMN2 exon 7 inclusion and SMN protein expression in intestine in SMA
mice, we have shown that systemic PMO25 administration directly targets SMN2 exon 7 splic-
ing in intestine. This provides new insight into the biodistribution of PMO25 in vivo. While
SMA is widely accepted as a lower motor neuron disease with spinal motor neurons being the
primary pathological target, the involvement of additional peripheral organs has been impli-
cated to contribute to the pathogenesis of the disease [18,19,42]. It is becoming increasingly
important to understand in which organs there is a requirement for SMN protein, as interven-
tions acting exclusively on the CNS will not address the peripheral manifestations of the disease
and could affect long term outcomes in some ongoing clinical studies, especially in severe type
I SMA infants.
In conclusion, we have shown significant histopathological abnormalities in intestine of
SMAmice and that these abnormalities are reversed to near-normal by systemic PMO25
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treatment. We speculate that enteric vascular defects, secondary to SMN deficiency, are
responsible for the pathological changes in the intestine. This study provides crucial insight
into potential additional therapeutic targets and will facilitate the development of future
therapies.
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